Kelly Goldsmith

Department of Pediatrics
Professor

Aflac Cancer and Blood Disorders Center
Pediatrics
1760 Haygood Drive

Academic Appointment

Associate Professor of Pediatrics, Emory University

Education

Degrees

MD from University of Alabama School of Medicine
BS from Duke University

Research

Focus

My research focuses on the molecular mechanisms of chemoresistance in neuroblastoma (NB), a highly lethal pediatric solid tumor, and on the use of experimental therapeutics to restore therapy sensitivity through the re-engagement of programmed cell death.

Publications

Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.
Pediatr Blood Cancer Volume: 72 Page(s): e31714
07/01/2025 Authors: Karol SE; Khaw SL; Zwaan CM; Baruchel A; Bittencourt H; Cooper TM; Flotho C; Fraser C; Forlenza CJ; Goldsmith KC
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
J Clin Oncol Page(s): JCO2402612
06/23/2025 Authors: Cash T; Marachelian A; DuBois SG; Chi Y-Y; Baregamyan A; Groshen SG; Jonus HC; Shamirian A; Crowley M; Goodarzian F
Protocol for 3D bioprinting of a 3D in vitro model of neuroblastoma.
STAR Protoc Volume: 6 Page(s): 103725
06/20/2025 Authors: Amoli MS; Rezapourdamanab S; Jin L; Cadena MA; Kaw K; Sridhar V; Meselhe M; Krikor S; Mahmoudi M; Ning L
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.
Pediatr Blood Cancer Page(s): e31831
06/12/2025 Authors: DuBois SG; Moreno L; Anderson J; Asgharzadeh S; Bagatell R; Beck-Popovic M; Belle J; Berlanga P; Bird NJ; Chesler L
Trends in analgesia-sedation of pediatric patients receiving I-131 MIBG in the pediatric intensive care unit: A report from the Pediatric Health Information System database.
Pediatr Blood Cancer Volume: 71 Page(s): e31205
10/01/2024 Authors: Dhuse J; Cash T; Elges MS; Alazraki A; Beer R; Jergel A; Goldsmith KC; Hall M; Kamat PP
Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma.
J Natl Compr Canc Netw Volume: 22
08/01/2024 Authors: Irwin MS; Goldsmith KC
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
Commun Biol Volume: 7 Page(s): 426
04/08/2024 Authors: Mittal K; Cooper GW; Lee BP; Su Y; Skinner KT; Shim J; Jonus HC; Kim WJ; Doshi M; Almanza D
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
Pediatr Blood Cancer Volume: 70 Suppl 6 Page(s): e30572
09/01/2023 Authors: Bagatell R; DuBois SG; Naranjo A; Belle J; Goldsmith KC; Park JR; Irwin MS; COG Neuroblastoma Committee
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Volume: 70 Page(s): e30405
08/01/2023 Authors: Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma.
Cell Rep Med Volume: 4 Page(s): 101091
06/20/2023 Authors: Lee JY; Jonus HC; Sadanand A; Branella GM; Maximov V; Suttapitugsakul S; Schniederjan MJ; Shim J; Ho A; Parwani KK
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Nat Commun Volume: 14 Page(s): 2601
05/05/2023 Authors: Berko ER; Witek GM; Matkar S; Petrova ZO; Wu MA; Smith CM; Daniels A; Kalna J; Kennedy A; Gostuski I
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Nat Med Volume: 29 Page(s): 1092 - 1102
05/01/2023 Authors: Goldsmith KC; Park JR; Kayser K; Malvar J; Chi Y-Y; Groshen SG; Villablanca JG; Krytska K; Lai LM; Acharya PT
The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1.
Oncoimmunology Volume: 12 Page(s): 2240678
01/01/2023 Authors: Pilgrim AA; Jonus HC; Ho A; Cole AC; Shim J; Goldsmith KC
Identification of a Novel NRG1 Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case Report.
Case Rep Oncol Volume: 16 Page(s): 249 - 255
01/01/2023 Authors: Mitchell SG; Basu GD; Eaton B; Goodman LJ; Goldsmith KC
VENETOCLAX IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS: UPDATED FINDINGS FROM A PHASE 1 STUDY
Volume: 69
11/01/2022 Authors: Morgenstern D; Khaw S; Gerber N; Place A; Corradini N; Loh M; Verschuur A; Ziegler D; Fraser C; Cooper T
A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior.
Adv Sci (Weinh) Volume: 9 Page(s): e2200244
08/01/2022 Authors: Ning L; Shim J; Tomov ML; Liu R; Mehta R; Mingee A; Hwang B; Jin L; Mantalaris A; Xu C
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance.
EMBO J Volume: 41 Page(s): e108272
04/19/2022 Authors: oku J; Booth DM; Skoda J; Pedrotty MC; Vogel J; Liu K; Vu A; Carpenter EL; Ye JC; Chen MA
Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.
JCO Precis Oncol Volume: 6 Page(s): e2100451
04/01/2022 Authors: Summers RJ; Castellino SM; Porter CC; MacDonald TJ; Basu GD; Szelinger S; Bhasin MK; Cash T; Carter AB; Castellino RC
Dissecting the cellular components of ex vivo T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials.
Oncoimmunology Volume: 11 Page(s): 2057012
01/01/2022 Authors: Jonus HC; Burnham RE; Ho A; Pilgrim AA; Shim J; Doering CB; Spencer HT; Goldsmith KC
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
J Clin Oncol Volume: 39 Page(s): 3506 - 3514
11/01/2021 Authors: DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H
A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment.
Cancers (Basel) Volume: 13
09/16/2021 Authors: Shim J; Goldsmith KC
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Mol Cancer Ther Volume: 20 Page(s): 1161 - 1172
06/01/2021 Authors: Vernooij L; Bate-Eya LT; Alles LK; Lee JY; Koopmans B; Jonus HC; Schubert NA; Schild L; Lelieveld D; Egan DA
COMPARISON OF OBSERVED LORLATINIB PHARMACOKINETICS IN SPECIAL POPULATIONS TO SIMULATIONS BASED ON THE PRIOR POPULATION PHARMACOKINETIC (POPPK) MODEL DEVELOPED USING DATA FROM ADULT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).
Volume: 109 Page(s): S55 - S55
03/01/2021 Authors: Huynh D; Lin S; Mosse Y; Goldsmith K; Pithavala Y; Chen J
YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma.
Cancer Res Volume: 80 Page(s): 4741 - 4753
11/01/2020 Authors: Shim J; Lee JY; Jonus HC; Arnold A; Schnepp RW; Janssen KM; Maximov V; Goldsmith KC
NEXT-GENERATION SEQUENCING REVEALS INCREASED PREVALENCE OF PICALM-MLLT10 FUSIONS IN T-ALL AND T-LLY
Volume: 67 Page(s): S167 - S167
06/01/2020 Authors: Summers R; Aumann W; Pauly M; Goldsmith K; Porter C; Worsley R; Graham D; Castellino S; Wechsler D
Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.
Volume: 38
05/20/2020 Authors: DuBois SG; Granger M; Groshen SG; Tsao-Wei D; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Mosse YP
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Volume: 67 Page(s): e28134
04/01/2020 Authors: Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C
Multidisciplinary Care of Adult Wilms' Tumor During Pregnancy: A Case Report and Review of the Literature.
Clin Genitourin Cancer Volume: 18 Page(s): e1 - e4
02/01/2020 Authors: Brown JT; Harik LR; Barbee MS; Esiashvili N; Badell ML; Goldsmith KC; Master VA; Bilen MA
Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group.
Pediatr Blood Cancer Volume: 66 Page(s): e27920
10/01/2019 Authors: Esbenshade AJ; Kahalley LS; Baertschiger R; Dasgupta R; Goldsmith KC; Nathan PC; Harker-Murray P; Kitko CL; Kolb EA; Murphy ES
Predictive biomarkers for Bcl2-inhibitor use in neuroblastoma
Volume: 79
07/01/2019 Authors: Zapata C; Coku J; Liu K; Vu A; Goutnik M; Reynolds CP; Goldsmith K; Hogarty M
Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma.
Nat Commun Volume: 10 Page(s): 2410
06/03/2019 Authors: Maximov V; Chen Z; Wei Y; Robinson MH; Herting CJ; Shanmugam NS; Rudneva VA; Goldsmith KC; MacDonald TJ; Northcott PA
BCL2-INHIBITOR RESPONSE IN NEUROBLASTOMA: BIOMARKERS AND THERAPY RESISTANCE
Volume: 66
06/01/2019 Authors: Zapata C; Coku J; Liu K; Vu A; Goutnik M; Bodducherla R; Reynolds CP; Goldsmith K; Hogarty M
Ex vivo expanded patient-derived T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model.
Oncoimmunology Volume: 8 Page(s): 1593804
01/01/2019 Authors: Zoine JT; Knight KA; Fleischer LC; Sutton KS; Goldsmith KC; Doering CB; Spencer HT
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
Clin Cancer Res Volume: 24 Page(s): 6142 - 6149
12/15/2018 Authors: DuBois SG; Mosse YP; Fox E; Kudgus RA; Reid JM; McGovern R; Groshen S; Bagatell R; Maris JM; Twist CJ
The properties of ex vivo expanded gamma delta T cells provide for the rational use of combination therapies
Volume: 78
10/01/2018 Authors: Zoine JT; Sutton KS; Knight KA; Goldsmith KC; Doering CB; Spencer HT
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
Future Oncol Volume: 14 Page(s): 2115 - 2129
09/01/2018 Authors: Place AE; Goldsmith K; Bourquin J-P; Loh ML; Gore L; Morgenstern DA; Sanzgiri Y; Hoffman D; Zhou Y; Ross JA
TARGETING THE YES-ASSOCIATED PROTEIN IN NEUROBLASTOMA
Volume: 65
06/01/2018 Authors: Shim J; Janssen K; Arnold A; Lee YJ; Fritz A; Goldsmith K
Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.
Transfusion Volume: 58 Page(s): 1149 - 1156
05/01/2018 Authors: Runco DV; Josephson CD; Raikar SS; Goldsmith KC; Lew G; Pauly M; Fasano RM
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
Clin Cancer Res Volume: 23 Page(s): 5374 - 5383
09/15/2017 Authors: Marachelian A; Villablanca JG; Liu CW; Liu B; Goodarzian F; Lai HA; Shimada H; Tran HC; Parra JA; Gallego R
Concurrent myeloid sarcoma, atypical teratoid/rhabdoid tumor, and hypereosinophilia in an infant with a germline SMARCB1 mutation.
Pediatr Blood Cancer Volume: 64
09/01/2017 Authors: Metts JL; Park SI; Soares BP; Fong C; Biegel JA; Goldsmith KC
Engineering Ex Vivo Serum-Free Expanded (Y)delta T Cells for the Treatment of Neuroblastoma
Volume: 25 Page(s): 278 - 279
05/01/2017 Authors: Zoine JT; Sutton KS; Goldsmith KC; Dasgupta A; McCarty D; Doering CB; Spencer HT
Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement.
Int J Radiat Oncol Biol Phys Volume: 97 Page(s): 806 - 812
03/15/2017 Authors: Ferris MJ; Danish H; Switchenko JM; Deng C; George BA; Goldsmith KC; Wasilewski KJ; Cash WT; Khan MK; Eaton BR
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Cancer Med Volume: 5 Page(s): 1416 - 1424
07/01/2016 Authors: Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
BMC Cancer Volume: 16 Page(s): 97
02/13/2016 Authors: Tanos R; Karmali D; Nalluri S; Goldsmith KC
EGFR signaling defines Mcl1 survival dependency in neuroblastoma.
Cancer Biol Ther Volume: 16 Page(s): 276 - 286
01/01/2015 Authors: Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.
Cell Death Dis Volume: 5 Page(s): e1072
02/20/2014 Authors: Laetsch TW; Liu X; Vu A; Sliozberg M; Vido M; Elci OU; Goldsmith KC; Hogarty MD
EGFR regulates Mcl-1 dependence in chemoresistant and acquired ABT-737-resistant high-risk neuroblastoma (HR NB).
Volume: 73
04/15/2013 Authors: Peirce SK; Nalluri S; Abdella H; Goldsmith K
COUP-TF1 is a novel biomarker of therapy response in high-risk neuroblastoma
Volume: 73
04/15/2013 Authors: Abdella H; Nalluri S; Peirce SK; Goldsmith KC
Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma.
Cancer Res Volume: 72 Page(s): 2565 - 2577
05/15/2012 Authors: Goldsmith KC; Gross M; Peirce S; Luyindula D; Liu X; Vu A; Sliozberg M; Guo R; Zhao H; Reynolds CP
A synthetic-lethal screen identifies novel Mc11 regulators in neuroblastorna
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Laetsch T; Liu X; Sliozberg M; Vido M; Vu A; Goldsmith K; Hogarty MD
BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.
Cell Death Differ Volume: 17 Page(s): 872 - 882
05/01/2010 Authors: Goldsmith KC; Lestini BJ; Gross M; Ip L; Bhumbla A; Zhang X; Zhao H; Liu X; Hogarty MD
Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
Cancer Biol Ther Volume: 8 Page(s): 1587 - 1595
08/01/2009 Authors: Lestini BJ; Goldsmith KC; Fluchel MN; Liu X; Chen NL; Goyal B; Pawel BR; Hogarty MD
Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
Curr Opin Investig Drugs Volume: 10 Page(s): 559 - 571
06/01/2009 Authors: Goldsmith KC; Hogarty MD
RNA interference reveals heterogeneous pro-survival BH protein addiction and therapy resistance patterns in neuroblastoma
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Lestini B; Goldsmith K; Chen N; Liu X; Hogarty M
The role of McI1 as a pro-survival protein in neuroblastoma
PEDIATRIC BLOOD & CANCER Volume: 48 Page(s): 640 - 640
06/01/2007 Authors: Fluchel MN; Lin A; Goldsmith KC; Liu X; Davis K; Bhumbla A; Ip L; London W; Hogarty MD
Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).
Blood Volume: 108 Page(s): 1965 - 1971
09/15/2006 Authors: Teachey DT; Obzut DA; Axsom K; Choi JK; Goldsmith KC; Hall J; Hulitt J; Manno CS; Maris JM; Rhodin N
BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.
Oncogene Volume: 25 Page(s): 4525 - 4533
08/03/2006 Authors: Goldsmith KC; Liu X; Dam V; Morgan BT; Shabbout M; Cnaan A; Letai A; Korsmeyer SJ; Hogarty MD
BH3-domain peptides synergize with cytotoxic agents to restore apoptosis sensitivity in chemoresistant neuroblastoma
Volume: 66
04/01/2006 Authors: Goldsmith K; Liu X; Goyal B; Lin A; Thambinayagan C; Davis K; Hogarty M
Single-stranded conformational polymorphism analysis improves radioactive detection of unequal X-inactivation - a case of childhood myelodysplastic syndrome.
Volume: 7 Page(s): 691 - 691
11/01/2005 Authors: Wildemore BM; Carlin A; Wang H; Goldsmith K; Kwiatkowski JL; Biegel J; Wilmoth D; Choi JK; Edmonston TB
Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.
Cancer Lett Volume: 228 Page(s): 133 - 141
10/18/2005 Authors: Goldsmith KC; Hogarty MD
Rhabdomyosarcoma arising in a giant congenital melanocytic nevus.
Cutis Volume: 73 Page(s): 39 - 43
01/01/2004 Authors: Ilyas EN; Goldsmith K; Lintner R; Manders SM

Directory section navigation

Profile

Kelly Goldsmith

Academic Appointment

Education

Degrees

Research

Focus

Publications